Anna Episodic migraine patient

  • Anna’s migraine gets in the way of her professional responsibilities

  • She is currently on an oral preventive treatment, but she continues to experience migraine days

  • Anna would like the flexibility to choose a dosing option

" Is AJOVY right for me? "

Significantly more migraine-free days with AJOVY vs placebo1

In episodic migraine, a reduction in monthly migraine days was demonstrated during the 12-week period (primary endpoint), with results seen as early as week 11,2

  • Patients with a mean baseline of 8.9 migraine days per month experienced 3.7 fewer migraine days per month, on average, with monthly dosing (vs 2.2 with placebo)1*
  • 47.7% of patients with episodic migraine achieved at least a 50% reduction in monthly average migraine days with monthly dosing vs 27.9% for placebo (secondary endpoints)1*

SEE EFFICACY DATA FOR AJOVY

Flexibility to help you meet your patients' needs1

Image Image

  • Administration at home by a patient or caregiver or in office by a healthcare professional
    • Guidance on proper subcutaneous administration techniques should be provided
  • The most common adverse reaction (≥5% and greater than placebo) were injection-site reactions1

SEE DOSING OPTIONS FOR AJOVY

Study design1-3

AJOVY was evaluated in two phase 3, 12-week, randomized, double-blind, placebo-controlled, parallel-group trials

  • In the episodic migraine trial, the primary endpoint, for both quarterly and monthly dosing, was the mean change from baseline in the monthly average number of migraine days during the 12-week period

SEE CLINICAL TRIAL DESIGNS SQ: subcutaneous. *P<0.001.1 Patients with a mean baseline of 9.2 migraine days per month experienced 3.4 fewer migraine days per month, on average, with quarterly dosing vs 2.2 days with placebo, P<0.001.1 44.4% of patients with episodic migraine achieved at least a 50% reduction in monthly average migraine days with quarterly dosing vs 27.9% for placebo, P<0.001.1

Suggestions to explore next

Continue to AJOVY Efficacy page

AJOVY helped significantly reduce monthly migraine days vs placebo1

see the clinical trial data for ajovy
Continue to AJOVY Dosing flexibility page

Flexibility to help you meet your patients' needs1

dosing options for ajovy
Continue to AJOVY Safety page

Safety profile in clinical trials for AJOVY1

safety profile for ajovy